Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Hervé Bonnefoi, Saskia Litière, Martine Piccart, +16

Annals of Oncology

Breast OncologyEortc 10994/BigMedicinePathologyPathological Complete Response +5

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Solène De Talhouet, Julien Péron, Aurélie Vuilleumier, +14

Scientific Reports

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson, +249

The Lancet Oncology

Breast OncologyMedicineCancer ManagementGynecologyBreast Cancer +5

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Hervé Bonnefoi, William Jacot, Mahasti Saghatchian, +15

Annals of Oncology

Breast OncologyMedicinePathologyNeoadjuvant TreatmentAnthracycline-based Chemotherapy +6

Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor

Kamal Ahmed, Alexey Koval, Jiabin Xu, +2

Cancer Letters

First Targeted TherapyBreast OncologyMedicinePharmacologyImmune Checkpoint Inhibitor +8

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Andreas F. Hottinger, Assma Ben Aïssa, Vittoria Espeli, +9

British Journal of Cancer

Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer

Sana Intidhar Labidi‐Galy, Timothée Olivier, Manuel Rodrigues, +21

Clinical Cancer Research

Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging

Diomidis Botsikas, Anastasia Kalovidouri, Minerva Becker, +10

European Radiology

Medical ImagingClinical UtilityMedicineBreast CancerMri-guided Radiation Therapy +4

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

Christoph Mamot, Andreas Wicki, Ursula Hasler-Strub, +20

Scientific Reports

A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells

Marco Pupo, Alexandre Bodmer, Mélissa Berto, +3

Oncotarget

Breast OncologyGeneticsCancer BiologyTumor BiologyGper P16l Polymorphism +16